Quick Answer
Revolution Medicines, Inc. reported Stockholders Equity of $1.63 billion for the year ending 2025.
- Revolution Medicines, Inc. showed a decrease of -28.0% in Stockholders Equity from 2024 to 2025.
- This data is from Revolution Medicines, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$118.11 million | Q2 2019: -$127.70 million | Q3 2019: -$139.45 million | Q1 2020: $385.32 million | Q2 2020: $360.50 million | Q3 2020: $505.07 million | Q1 2021: $722.58 million | Q2 2021: $685.01 million | Q3 2021: $638.20 million | Q1 2022: $550.99 million | Q2 2022: $498.84 million | Q3 2022: $681.42 million | Q1 2023: $952.22 million | Q2 2023: $930.84 million | Q3 2023: $837.46 million | Q1 2024: $1.73 billion | Q2 2024: $1.62 billion | Q3 2024: $1.57 billion | Q1 2025: $2.08 billion | Q2 2025: $1.87 billion | Q3 2025: $1.60 billion.
- Over the full 9 years of available data (2017 to 2025), Revolution Medicines, Inc.'s Stockholders Equity has grown by 2,509.0%.
- Historical annual values: Fiscal year 2025: $1.63 billion | Fiscal year 2024: $2.27 billion | Fiscal year 2023: $1.83 billion | Fiscal year 2022: $685.19 million | Fiscal year 2021: $602.57 million | Fiscal year 2020: $474.68 million | Fiscal year 2019: -$152.57 million | Fiscal year 2018: -$108.42 million | Fiscal year 2017: -$67.72 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: